



Poster Presentations

FRIDAY, APRIL 17 | 10:15-11:00A

SCREEN / TIME

Four-Year Survival Outcomes With dostarlimab Plus Chemotherapy in dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer in the ENGOT-EN6 NSGO/GOG-3031/RUBY Trial

1

Management of White Bagging and Third-Party Medications at a Multi-Site System

2

tarlatamab With First-Line Chemo-Immunotherapy for Extensive-Stage Small Cell Lung Cancer: DeLLphi-303 Study

3

montelukast Prophylaxis for rituximab Infusion-Related Reactions: a Retrospective Analysis

4

Real-World Patient and Caregiver Experiences With Breast Cancer Risk of Recurrence in the United States: Results of an Online Survey and Social Media Analysis

5

Optimizing the Caregiver Experience During Bispecific Antibody Step-Up Therapy Through a Collaborative Inpatient and Outpatient Nursing Process

6

Role of a Hematology/Oncology Clinic-Based Specialty Pharmacist in Precision Therapy for Recurrent Glioblastoma

7

Pancreatic Cancer End-of-Life Care Is Shifting Toward Hospice, but Inequities Persist

8

Early Response Matters: Applying the Response to ruxolitinib After 6 Months Model to Optimize JAK Inhibitor Therapy in Myelofibrosis

9

Identifying Opportunities for c-MET Biomarker Testing and telisotuzumab vedotin Treatment in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Review

10

Real-World Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treatment Patterns at Florida Cancer Specialists & Research Institute Among Patients Receiving zanubrutinib Immediately Following Prior Bruton Tyrosine Kinase Inhibitor Therapy

11

NCODA's Immunotherapy Hub: A Centralized Resource for Navigating Bispecific T-Cell Engagers

12